IRF9 and TOP1

Number of citations of the paper that reports this interaction (PubMedID 12549820)
3

Data Source:
BioGRID (unspecified method)

		IRF9	TOP1
Description		interferon regulatory factor 9	DNA topoisomerase I
Image		No pdb structure
GO Annotations	Cellular Component	Chromatin Nucleus Nucleoplasm Cytoplasm Cytosol	Nuclear Chromosome P-body Fibrillar Center Nucleus Nucleoplasm Nucleolus Protein-DNA Complex Perikaryon
	Molecular Function	RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific DNA-binding Transcription Factor Activity Protein Binding Sequence-specific Double-stranded DNA Binding	RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA Binding Chromatin Binding Double-stranded DNA Binding Single-stranded DNA Binding RNA Binding DNA Topoisomerase Type I (single Strand Cut, ATP-independent) Activity Protein Serine/threonine Kinase Activity Protein Binding ATP Binding Protein Domain Specific Binding Supercoiled DNA Binding
	Biological Process	Immune System Process Regulation Of Transcription By RNA Polymerase II Transcription By RNA Polymerase II Cell Surface Receptor Signaling Pathway Defense Response To Virus	DNA Replication DNA Topological Change Chromatin Remodeling Chromosome Segregation Circadian Rhythm Programmed Cell Death Phosphorylation Peptidyl-serine Phosphorylation Circadian Regulation Of Gene Expression Embryonic Cleavage
Pathways		Interferon gamma signaling Interferon alpha/beta signaling	SUMOylation of DNA replication proteins
Drugs			Irinotecan Topotecan Camptothecin Edotecarin Lucanthone Elsamitrucin 7-ethyl-10-hydroxycamptothecin Sodium stibogluconate Cositecan XMT-1001 Rubitecan 2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM 4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE Hexylresorcinol Sacituzumab govitecan Trastuzumab deruxtecan
Diseases
GWAS			Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction) ( 28560309) Antipsychotic drug-induced weight gain in schizophrenia ( 31447353) Brain morphology (MOSTest) ( 32665545) Cholesterol, total ( 24097068 20686565) Fasting glucose ( 33402679) Hemoglobin ( 32888494) Hip circumference adjusted for BMI ( 34021172) LDL cholesterol ( 24097068 20686565) LDL cholesterol levels ( 28334899) LDL cholesterol levels x long total sleep time interaction (2df test) ( 31719535) LDL cholesterol levels x short total sleep time interaction (2df test) ( 31719535) Liver enzyme levels (gamma-glutamyl transferase) ( 33972514) Male-pattern baldness ( 28196072) Metabolite levels ( 23823483) PR interval ( 32439900) Red blood cell count ( 32888494) Refractive error ( 32231278) Total cholesterol levels ( 28334899) Urate levels ( 31578528) Waist-hip index ( 34021172) Waist-to-hip ratio adjusted for BMI ( 34021172)
Interacting Genes		20 interacting genes: ARID3B DACH2 DEDD DMRTC2 HOXC9 IFNA1 IRF1 IRF2BP1 MYO1F NFKB1 NR2E3 POU2F1 RELA S100A13 STAT1 STAT2 TLX2 TLX3 TOP1 VENTX	61 interacting genes: APAF1 APP ATM BARD1 BRCA1 BRD2 BTBD1 BTBD2 BUB3 CASP3 CASP6 CDK8 CKAP5 CSNK2A1 CSNK2A2 DDB2 ELK3 ERCC8 ERG FSHR GEMIN4 IL7R IRF4 IRF8 IRF9 JAK1 JUN KMT2A LIG4 LSM4 MDM2 NCL NCOA6 PDE10A PIAS4 PPP2R2B PRB1 PRKDC PYGM RBL1 RBL2 RCVRN SF3B1 SFPQ SNRNP70 SNW1 SRPK2 SRSF1 SRSF11 SUMO1 SYMPK TARBP2 TDP1 TOPORS TP53 TRIM32 TUBD1 U2AF2 UBE2I XRCC5 XRCC6
Entrez ID		10379	7150
HPRD ID		00960	00535
Ensembl ID		ENSG00000213928	ENSG00000198900
Uniprot IDs		Q00978	P11387 Q9BVT2
PDB IDs			1A31 1A35 1A36 1EJ9 1K4S 1K4T 1LPQ 1NH3 1R49 1RR8 1RRJ 1SC7 1SEU 1T8I 1TL8
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?